Companies / Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc.
Nasdaq: ACRVCIK 1781174WATERTOWN, MA
Financials
Ownership
42.9M shares outstanding · as of Aug 7, 2026
Ownership
| Insiders | 5.98% | 2,561,128 |
| Institutions | 24.87% | 10,656,742 |
| Public float | 69.16% | 29,635,492 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 14
View all →| Insider | % of shares | Shares |
|---|---|---|
Blume-Jensen PeterCEOPresident and CEO · Director | 5.59% | 2,394,331 |
Devroe EricChief Operating Officer | 0.17% | 74,585 |
Miller MaryChief Legal Officer | 0.08% | 33,679 |
Levy Adam D.Chief Financial Officer | 0.05% | 20,983 |
Gamelin ErickChief Development Officer | 0.03% | 14,812 |
Magovcevic-Liebisch IvanaDirector | 0.02% | 9,366 |
RA Capital Management, L.P.Director · 10% owner | 0.02% | 9,366 |
Peterson KatharineChief Accounting Officer | <0.01% | 4,006 |
Kolchinsky PeterDirector · 10% owner | — | — |
Masson KristinaEVP - Business Operations · Director | — | — |
Institutional holders 50
View all →| Holder | Value | % of shares |
|---|---|---|
| $11.59M | 19.46% | |
| $5.12M | 4.95% | |
| $3.96M | 3.83% | |
| $2.14M | 2.07% | |
| $1.68M | 1.63% | |
| $1.05M | 1.77% | |
| $976.6K | 0.95% | |
| $840.0K | 0.81% | |
| $824.4K | 0.80% | |
| $804.4K | 0.78% |
Activity
Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Q1 2026 as of | Millennium Management LLC 13F manager | Exit | Common Stock | $-292.9K | -122K -100.00% | — | low |
| Q1 2026 as of | Two Sigma Investments, LP 13F manager | Trim | Common Stock | $-272.0K | -196K -33.44% | 389,395 0.91% of shares | low |
| Q1 2026 as of | Renaissance Technologies LLC 13F manager | Add | Common Stock | $172.7K | +124K +19.60% | 758,440 1.77% of shares | low |
| Q1 2023 as of | Barclays PLC 13F manager | Add | Common Stock | $163.0K | +13K +310.02% | 16,983 0.04% of shares | low |
| Q1 2026 as of | Bridgeway Capital Management, LLC 13F manager | Add | Common Stock | $161.2K | +116K +270.40% | 158,900 0.37% of shares | low |
| Q1 2026 as of | Marshall Wace, LLP 13F manager | Add | Common Stock | $89.5K | +64K +12.97% | 560,436 1.31% of shares | low |
| Q3 2024 as of | Barclays PLC 13F manager | Add | Common Stock | $78.9K | +11K +51.16% | 33,306 0.08% of shares | low |
| Q4 2025 as of | Bluefin Capital Management, LLC 13F manager | Exit | Common Stock | $-76.1K | -42K -100.00% | — | low |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| ACRV | Common Stock | 004890109 |